| Literature DB >> 34765541 |
Xiangming Cai1, Junhao Zhu2,3, Jin Yang3, Chao Tang3, Feng Yuan2,3, Zixiang Cong2,3, Chiyuan Ma1,2,3,4.
Abstract
BACKGROUND: Pituitary adenomas (PAs) are the most common tumor of the sellar region. PA resection is the preferred treatment for patients with clear indications for surgery. Intraoperative cerebrospinal fluid (iCSF) leakage is a major complication of PA resection surgery. Risk factors for iCSF leakage have been studied previously, but a predictive nomogram has not yet been developed. We constructed a nomogram for preoperative prediction of iCSF leakage in endoscopic pituitary surgery.Entities:
Keywords: albumin; cerebrospinal fluid leakage; endoscopic pituitary surgery; nomogram; pituitary tumors; tumor height
Year: 2021 PMID: 34765541 PMCID: PMC8576331 DOI: 10.3389/fonc.2021.719494
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Important characteristics of patients in the without iCSF leakage group and in the with iCSF leakage group.
| Characteristics | Without iCSF leakage | With iCSF leakage |
|
|---|---|---|---|
| Gender | 0.060 | ||
| Female | 41 (47.1%) | 45 (63.4%) | |
| Male | 46 (52.9%) | 26 (36.6%) | |
| Primary-recurrence subtype | 0.227 | ||
| Primary | 78 (89.7%) | 58 (81.7%) | |
| Recurrence | 9 (10.3%) | 13 (18.3%) | |
| Lengths of tumor maximum dimension (mm) | 24.69 ± 8.44 | 28.62 ± 11.4 | 0.092 |
| Lengths of tumor height (mm) | 20.48 ± 8.31 | 26.3 ± 12.05 | 0.006* |
| Lengths of tumor width (mm) | 21.76 ± 5.37 | 24.07 ± 8.64 | 0.208 |
| Lengths of tumor thickness (mm) | 18.1 ± 5.93 | 22.14 ± 8.76 | 0.009* |
| Tumor volume (mm3) | 4.88 ± 4.23 | 10.18 ± 11.31 | 0.016* |
| Tumor shape 1 | 0.025* | ||
| In sella | 13 (19.4%) | 5 (9.3%) | |
| Hourglass sign | 27 (40.3%) | 35 (64.8%) | |
| Ellipsoid | 27 (40.3%) | 14 (25.9%) | |
| Tumor shape 2 | 0.019* | ||
| Not lobulated | 63 (94%) | 42 (77.8%) | |
| Lobulated | 4 (6%) | 12 (22.2%) | |
| Sellar barrier | 0.042* | ||
| Weak | 18 (26.9%) | 25 (46.3%) | |
| Strong | 49 (73.1%) | 29 (53.7%) | |
| Knosp grade | 0.192 | ||
| Noninvasive | 56 (65.9%) | 38 (54.3%) | |
| Invasive | 29 (34.1%) | 32 (45.7%) | |
| Pituitary apoplexy | 0.335 | ||
| No | 66 (76.7%) | 48 (68.6%) | |
| Yes | 20 (23.3%) | 22 (31.4%) | |
| Acromegalia | 0.701 | ||
| No | 73 (83.9%) | 57 (80.3%) | |
| Yes | 14 (16.1%) | 14 (19.7%) | |
| TSH (mIU/L) | 1.83 ± 1.18 | 2.37 ± 1.94 | 0.151 |
| T3 (nmol/L) | 1.21 ± 0.35 | 1.31 ± 0.31 | 0.049* |
| T4 (nmol/L) | 95.22 ± 22.88 | 100.72 ± 25 | 0.173 |
| Monocyte percentage (%) | 7.43 ± 1.75 | 6.96 ± 1.32 | 0.098 |
| APTT (s) | 26.67 ± 3.77 | 27.43 ± 3.37 | 0.206 |
| Fibrinogen (g/L) | 2.64 ± 0.68 | 2.73 ± 0.75 | 0.537 |
| Albumin (g/L) | 40.33 ± 3.69 | 39.65 ± 4.12 | 0.351 |
TSH, thyroid-stimulating hormone; T3, triiodothyronine; T4, tetraiodothyronine; APTT, activated partial thromboplastin time; iCSF, intraoperative cerebrospinal fluid. *Statistical significance.
Figure 1LASSO regression analysis using 10-fold cross-validation. AUC, area under the curve.
Univariate and multivariate logistic regression analysis for the final model.
| Characteristics | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Coefficient | OR | 95% CI |
| Coefficient | OR | 95% CI |
| |
| Lengths of tumor height (mm) | 0.0768 | 1.0798 | 1.0299-1.1321 | 0.0015* | 0.1081 | 1.1141 | 1.0485-1.1839 | 0.0005* |
| Albumin (g/L) | -0.0757 | 0.9271 | 0.8304-1.0350 | 0.1779 | -0.1395 | 0.8698 | 0.7576-0.9986 | 0.0477* |
CI, confidence interval; OR, odds ratio. *Statistical significance.
Figure 2Nomogram for preoperatively predicting the proportion of iCSF leakage during endoscopic pituitary surgery in patients with pituitary tumor.
Figure 3Predictive performance of the nomogram. (A, C, D) ROC analysis of nomogram in training cohort (A), validation cohort 1 (C), and validation cohort 2 (D). (B) Calibration plots of the nomogram. AUC, area under the curve.
ROC analysis in subgroups from validation cohort 1 and 2.
| Subgroups | AUC 1 | AUC 2 |
|---|---|---|
| Age | ||
| >51 years | 0.562 | 0.627 |
| ≤51 years | 0.625 | 0.647 |
| Gender | ||
| Female | 0.417 | 0.587 |
| Male | 0.844 | 0.705 |
| Clinical subtype | ||
| Nonfunctioning | 0.611 | 0.625 |
| PRL secreting | NA | 0.600 |
| GH secreting | 0.750 | 0.714 |
| ACTH secreting | NA | NA |
| Primary-recurrence subtype | ||
| Primary | 0.708 | 0.619 |
| Recurrence | 0.500 | 0.829 |
| Maximum dimension | ||
| Microadenoma (<10 mm) | NA | 0.500 |
| Macroadenoma (10–40 mm) | 0.727 | 0.669 |
| Giant adenoma (≥40 mm) | NA | 0.867 |
| Knosp grade | ||
| Noninvasive | 0.600 | 0.571 |
| Invasive | 0.800 | 0.789 |
| Hardy grade for sellar invasion | ||
| Noninvasive | 0.675 | 0.631 |
| Invasive | 0.611 | 0.500 |
| Lengths of tumor height | ||
| >23.6mm | 0.667 | 0.611 |
| ≤23.6mm | 0.500 | 0.490 |
| Albumin | ||
| >41g/L | 0.562 | 0.627 |
| ≤41g/L | 0.750 | 0.647 |
PRL secreting, prolactin secreting; GH secreting, growth hormone secreting; ACTH secreting, adrenocorticotropic hormone secreting. AUC 1, area under curve for validation cohort 1; AUC 2, area under curve for validation cohort 2; NA, Not applicable.